{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"345"},{"groupId":"OG001","value":"351"}]}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","value":"145"},{"groupId":"OG001","value":"153"}]}],"title":"EOT"}],"denoms":[{"counts":[{"groupId":"OG000","value":"360"},{"groupId":"OG001","value":"362"}],"units":"Participants"}],"description":"Pain response was defined as 30% reduction from Baseline in Brief Pain Inventory-Short Form (BPI-SF) worst pain score over the last 24 hours without an increase in analgesic (oral morphine equivalents) use at 2 consecutive evaluations. The BPI-SF contains 15 items designed to capture the pain severity (\"worst,\" \"least,\" \"average,\" and \"now\" \\[current pain\\]), pain location, medication to relieve the pain, and the interference of pain with various daily activities including general activity, mood, walking activity, normal work, relations with other people, sleep, and enjoyment of life. The pain severity items are rated on a 0 to 10 scale where: 0=no pain and 10=pain as bad as you can imagine and averaged for a total score of 0 (best) to 10 (Worst).","groups":[{"description":"Ixazomib 4 mg, capsules, orally, once, on Days 1, 8 and 15; plus lenalidomide 25 mg, orally, once, on Days 1 through 21; and dexamethasone 40 mg, orally, once, on Days 1, 8, 15 and 22 of a 28-day cycle for multiple cycles until PD or unacceptable toxicity, whichever occurred first up to EOT (up to approximately 42.9 months).","id":"OG000","title":"Ixazomib+ Lenalidomide + Dexamethasone"},{"description":"Ixazomib placebo-matching capsules, orally, once, on Days 1, 8 and 15; plus lenalidomide 25 mg, orally, once, on Days 1 through 21; and dexamethasone 40 mg, orally, once, on Days 1, 8, 15 and 22 of a 28-day cycle for multiple cycles until PD or unacceptable toxicity, whichever occurred first (up to approximately 41 months).","id":"OG001","title":"Placebo + Lenalidomide + Dexamethasone"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"ITT population included all randomized participants.","reportingStatus":"POSTED","timeFrame":"Baseline and end of treatment (EOT) (up to approximately 38 months)","title":"Number of Participants With Change From Baseline in Pain Response","type":"SECONDARY","unitOfMeasure":"Participants"}